

[standards.ieee.org/about/sba/dec2010.html](http://standards.ieee.org/about/sba/dec2010.html).

On September 17, 2004, IEEE filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on November 3, 2004 (69 FR 64105).

The last notification was filed with the Department on July 22, 2010. A notice was published in the **Federal Register** pursuant to Section 6(b) of the Act on September 9, 2010 (75 FR 54915).

**Patricia A. Brink,**

*Director of Civil Enforcement, Antitrust Division.*

[FR Doc. 2011-2076 Filed 2-1-11; 8:45 am]

**BILLING CODE 4410-11-M**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Importer of Controlled Substances; Notice of Application**

Pursuant to Title 21 Code of Federal Regulations 1301.34(a), this is notice that on November 9, 2010, Mallinckrodt Inc., 3600 North Second Street, St. Louis, Missouri 63147, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of the following basic classes of controlled substances:

Drug	Schedule
Phenylacetone (8501) .....	II
Coca Leaves (9040) .....	II
Opium, raw (9600) .....	II
Poppy Straw Concentrate (9670)	II

The company plans to import the listed controlled substances for the manufacture of controlled substances in bulk for distribution to its customers.

No comments, objections, or requests for any hearings will be accepted on any application for registration or re-registration to import crude opium, poppy straw, concentrate of poppy straw or coca leaves. As explained in the Correction to Notice of Application pertaining to Rhodes Technologies, 72 FR 3417 (2007), comments and requests for hearings on applications to import narcotic raw material are not appropriate.

Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances listed in schedule I or II, which fall under the authority of section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in the circumstances

set forth in 21 U.S.C. 958(i), file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47.

Any such comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, **Federal Register** Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than March 4, 2011.

This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the **Federal Register** on September 23, 1975, (40 FR 43745), all applicants for registration to import a basic class of any controlled substance in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

Dated: January 18, 2011.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 2011-2289 Filed 2-1-11; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Importer of Controlled Substances; Notice of Registration**

By Notice dated June 17, 2010, and published in the **Federal Register** on June 28, 2010, (75 FR 36681), Research Triangle Institute, Kenneth H. Davis, Jr., Hermann Building, East Institute Drive, P.O. Box 12194, Research Triangle, North Carolina 27709, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the following basic classes of controlled substances:

Drug	Schedule
1-(1-Phenylcyclohexyl)pyrrolidine (7458).	I
1-[1-(2-Thienyl)cyclohexyl]piperidine (7470).	I

Drug	Schedule
1-[1-(2-Thienyl)cyclohexyl]pyrrolidine (7473).	I
1-Methyl-4-phenyl-4-propionoxypiperidine (9661).	I
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine (9663).	I
2,5-Dimethoxy-4-(n-propylthiophenethylamine (7348).	I
2,5-Dimethoxy-4-ethylamphetamine (7399).	I
2,5-Dimethoxyamphetamine (7396).	I
3,4,5-Trimethoxyamphetamine (7390).	I
3,4-Methylenedioxyamphetamine (7400).	I
3,4-Methylenedioxyamphetamine (7405).	I
3,4-Methylenedioxy-N-ethylamphetamine (7404).	I
3-Methylfentanyl (9813) .....	I
3-Methylthiofentanyl (9833) .....	I
4-Bromo-2,5-dimethoxyamphetamine (7391).	I
4-Bromo-2,5-dimethoxyphenethylamine (7392).	I
4-Methyl-2,5-dimethoxyamphetamine (7395).	I
4-Methylaminorex (cis isomer) (1590).	I
4-Methoxyamphetamine (7411) ...	I
5-Methoxy-3,4-methylenedioxyamphetamine (7401).	I
5-Methoxy-N,N-diisopropyltryptamine (7439).	I
Acetorphine (9319) .....	I
Acetyl-alpha-methylfentanyl (9815).	I
Acetyldihydrocodeine (9051) .....	I
Acetylmethadol (9601) .....	I
Allylprodine (9602) .....	I
Alphacetylmethadol except levo-alpha-cetylmethadol (9603).	I
Alpha-ethyltryptamine (7249) .....	I
Alphameprodine (9604) .....	I
Alphamethadol (9605) .....	I
Alpha-methylfentanyl (9814) .....	I
Alpha-methylthiofentanyl (9832) ...	I
Alpha-methyltryptamine (7432) ....	I
Aminorex (1585) .....	I
Benzethidine (9606) .....	I
Benzylmorphine (9052) .....	I
Betacetylmethadol (9607) .....	I
Beta-hydroxy-3-methylfentanyl (9831).	I
Beta-hydroxyfentanyl (9830) .....	I
Betameprodine (9608) .....	I
Betamethadol (9609) .....	I
Betaprodine (9611) .....	I
Bufotenine (7433) .....	I
Cathinone (1235) .....	I
Clonitazene (9612) .....	I
Codeine methylbromide (9070) ....	I
Codeine-N-Oxide (9053) .....	I
Cyprenorphine (9054) .....	I
Desomorphine (9055) .....	I
Dextromoramide (9613) .....	I
Diampromide (9615) .....	I
Diethylthiambutene (9616) .....	I

Drug	Schedule	Drug	Schedule
Diethyltryptamine (7434)	I	Thiofentanyl (9835)	I
Difenoxin (9168)	I	Tilidine (9750)	I
Dihydromorphine (9145)	I	Trimeperidine (9646)	I
Dimenoxadol (9617)	I	1-Phenylcyclohexylamine (7460)	II
Dimepheptanol (9618)	I	1-Piperidinocyclohexanecarbonitrile (8603)	II
Dimethylthiambutene (9619)	I	Alfentanil (9737)	II
Dimethyltryptamine (7435)	I	Alphaprodine (9010)	II
Dioxaphetyl butyrate (9621)	I	Amobarbital (2125)	II
Dipipanone (9622)	I	Amphetamine (1100)	II
Drotebanol (9335)	I	Anileridine (9020)	II
Ethylmethylthiambutene (9623)	I	Bezitramide (9800)	II
Etonitazene (9624)	I	Carfentanyl (9743)	II
Etorphine except HCl (9056)	I	Coca Leaves (9040)	II
Etoxadine (9625)	I	Cocaine (9041)	II
Fenethylamine (1503)	I	Codeine (9050)	II
Furethidine (9626)	I	Dextropropoxyphene, bulk (non-dosage forms) (9273)	II
Gamma Hydroxybutyric Acid (2010)	I	Dihydrocodeine (9120)	II
Heroin (9200)	I	Dihydroetorphine (9334)	II
Hydromorphanol (9301)	I	Diphenoxylate (9170)	II
Hydroxypethidine (9627)	I	Ethylmorphine (9190)	II
Ibogaine (7260)	I	Etorphine Hcl (9059)	II
Ketobemidone (9628)	I	Fentanyl (9801)	II
Levomoramide (9629)	I	Glutethimide (2550)	II
Levophenacetylmorphan (9631)	I	Hydrocodone (9193)	II
Lysergic acid diethylamide (7315)	I	Hydromorphone (9150)	II
Marihuana (7360)	I	Isomethadone (9226)	II
Mecloqualone (2572)	I	Levo-alphaacetylmethadol (9648)	II
Mescaline (7381)	I	Levomethorphan (9210)	II
Methaqualone (2565)	I	Levorphanol (9220)	II
Methcathinone (1237)	I	Lisdexamfetamine (1205)	II
Methyldesorphine (9302)	I	Meperidine (9230)	II
Methyl Dihydromorphine (9304)	I	Meperidine intermediate-A (9232)	II
Morpheridine (9632)	I	Meperidine intermediate-B (9233)	II
Morphine methylbromide (9305)	I	Meperidine intermediate-C (9234)	II
Morphine methylsulfonate (9306)	I	Metazocine (9240)	II
Morphine-N-Oxide (9307)	I	Methadone (9250)	II
Myrophine (9308)	I	Methadone intermediate (9254)	II
N,N-Dimethylamphetamine (1480)	I	Methamphetamine (1105)	II
N-Benzylpiperazine (7493)	I	Methylphenidate (1724)	II
N-Ethyl-3-piperidyl benzilate (7482)	I	Metopon (9260)	II
N-Ethylamphetamine (1475)	I	Moramide intermediate (9802)	II
N-Ethyl-1-phenylcyclohexylamine (7455)	I	Morphine (9300)	II
N-Hydroxy-3,4-methylenedioxyamphetamine (7402)	I	Nabilone (7379)	II
Nicocodeine (9309)	I	Opium, raw (9600)	II
Nicomorphine (9312)	I	Opium extracts (9610)	II
N-Methyl-3-piperidyl benzilate (7484)	I	Opium fluid extract (9620)	II
Noracetylmethadol (9633)	I	Opium tincture (9630)	II
Norlevorphanol (9634)	I	Opium, granulated (9640)	II
Normethadone (9635)	I	Oxycodone (9143)	II
Normorphine (9313)	I	Oxymorphone (9652)	II
Norpipanone (9636)	I	Pentobarbital (2270)	II
Para-Fluorofentanyl (9812)	I	Phenazocine (9715)	II
Parahexyl (7374)	I	Phencyclidine (7471)	II
Peyote (7415)	I	Phenmetrazine (1631)	II
Phenadoxone (9637)	I	Phenylacetone (8501)	II
Phenamipromide (9638)	I	Piminodine (9730)	II
Phenomorphane (9647)	I	Powdered opium (9639)	II
Phenoperidine (9641)	I	Racemethorphan (9732)	II
Pholcodine (9314)	I	Racemorphan (9733)	II
Piritramide (9642)	I	Remifentanyl (9739)	II
Proheptazine (9643)	I	Secobarbital (2315)	II
Propoperidine (9644)	I	Sufentanil (9740)	II
Propiram (9649)	I	Thebaine (9333)	II
Psilocybin (7437)	I		
Psilocyn (7438)	I		
Racemoramide (9645)	I		
Tetrahydrocannabinols (7370)	I		
Thebacon (9315)	I		

previously in this Notice of Registration, the Notice of Application (75 FR 36681), dated June 17, 2010, and published in the **Federal Register** on June 28, 2010, also stated that the Research Triangle Institute made application to be registered as an importer of the following schedule I controlled substances:

- N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl) (drug code: 9818)
- N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl) (drug code: 9834)

By Notice dated June 19, 2010, and published in the **Federal Register** on June 29, 2010, (75 FR 37300), the DEA issued a rulemaking in the form of a Final Rule to correct Title 21, Code of Federal Regulations (CFR), specifically: 21 CFR 1308.11(g), by deleting regulations which listed benzylfentanyl (drug code: 9818) and thenylfentanyl (drug code: 9834) as being temporarily subject to schedule I controls under the emergency scheduling provisions of the Controlled Substances Act (CSA). DEA determined that these compounds were both essentially inactive, with no evidence of abuse potential. Pursuant to June 19th rulemaking (75 FR 37300), effective June 29, 2010, both benzylfentanyl (drug code: 9818) and thenylfentanyl (drug code: 9834) were no longer legally deemed to be controlled substances. Thus, neither benzylfentanyl (drug code: 9818) nor thenylfentanyl (drug code: 9834) is listed in this Notice of Registration despite being originally listed in the Notice of Application. (75 FR 36681)

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Research Triangle Institute to import the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. DEA has investigated Research Triangle Institute to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed.

The company plans to import small quantities of the listed controlled substances for the National Institute on Drug Abuse (NIDA) for research activities.

In addition to the basic classes of controlled substances mentioned

Dated: January 18, 2011.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 2011-2284 Filed 2-1-11; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Application**

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 25, 2010, AMRI Rensselaer, Inc., 33 Riverside Avenue, Rensselaer, New York 12144, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Marihuana (7360) .....	I
Tetrahydrocannabinols (7370) .....	I
Amphetamine (1100) .....	II
Lisdexamfetamine (1205) .....	II
Methylphenidate (1724) .....	II
Pentobarbital (2270) .....	II
Meperidine (9230) .....	II
Fentanyl (9801) .....	II

The company plans to manufacture bulk controlled substances for use in product development and for distribution to its customers.

In reference to drug code 7360 (Marihuana), the company plans to bulk manufacture cannabidiol as a synthetic intermediate. This controlled substance will be further synthesized to bulk manufacture a synthetic THC (7370). No other activity for this drug code is authorized for this registration.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than April 4, 2011.

Dated: January 18, 2011.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 2011-2288 Filed 2-1-11; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Application**

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 24, 2010, Sigma Aldrich Research Biochemicals, Inc., 1-3 Strathmore Road, Natick, Massachusetts 01760-2447, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following classes of controlled substances:

Drug	Schedule
Cathinone (1235) .....	I
Methcathinone (1237) .....	I
Aminorex (1585) .....	I
Alpha-ethyltryptamine (7249) .....	I
Lysergic acid diethylamide (7315) .....	I
Tetrahydrocannabinols (7370) .....	I
4-Bromo-2,5-dimethoxyamphetamine (7391) .....	I
4-Bromo-2,5-dimethoxyphenethylamine (7392) .....	I
2,5-Dimethoxyamphetamine (7396) .....	I
3,4-Methylenedioxyamphetamine (7400) .....	I
N-Hydroxy-3,4-methylenedioxyamphetamine (7402) .....	I
3,4-Methylenedioxy-N-ethylamphetamine (7404) .....	I
3,4-Methylenedioxy-N-methylamphetamine (MDMA) (7405) .....	I
Psilocybin (7437) .....	I
5-Methoxy-N,N-diisopropyltryptamine (7439) .....	I
1-[1-(2-Thienyl)cyclohexyl]piperidine (TCP) (7470) .....	I
N-Benzylpiperazine (BZP) (7493) .....	I
Heroin (9200) .....	I
Normorphine (9313) .....	I
Amphetamine (1100) .....	II
Methamphetamine (1105) .....	II
Nabilone (7379) .....	II
1-Phenylcyclohexylamine (7460) .....	II
Phencyclidine (7471) .....	II
Cocaine (9041) .....	II
Codeine (9050) .....	II
Diprenorphine (9058) .....	II
Ecgonine (9180) .....	II
Levomethorphan (9210) .....	II
Levorphanol (9220) .....	II

Drug	Schedule
Meperidine (9230) .....	II
Metazocine (9240) .....	II
Methadone (9250) .....	II
Morphine (9300) .....	II
Thebaine (9333) .....	II
Levo-alphaacetylmethadol (9648) .....	II
Remifentanyl (9739) .....	II
Carfentanyl (9743) .....	II
Fentanyl (9801) .....	II

The company plans to manufacture reference standards.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than April 4, 2011.

Dated: January 18, 2011.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 2011-2237 Filed 2-1-11; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Registration**

By Notice dated August 3, 2010, and published in the **Federal Register** on September 1, 2010, 75 FR 53719, Cambridge Isotope Lab, 50 Frontage Road, Andover, Massachusetts 01810, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Morphine (9300), a basic class of controlled substance listed in schedule II.

The company plans to utilize small quantities of the listed controlled substance in the preparation of analytical standards.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Cambridge Isotope Lab to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has